Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 8/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | GRM5 | P41594 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12415887 | 0.88 | RXFP1 (0.56) | RXFP1THRBMAPTGRM5LMNA | |
| SCHEMBL12415869 | 0.85 | RXFP1 (0.47) | RXFP1THRBMAPTGRM5LMNA | |
| SCHEMBL12415867 | 0.85 | RXFP1 (0.54) | RXFP1THRBMAPTGRM5LMNA | |
| SCHEMBL12415805 | 0.84 | MAPT (0.52) | RXFP1THRBMAPTGRM5LMNA | |
| SCHEMBL12415865 | 0.84 | KMT2A (0.54) | HCAR2RXFP1THRBMAPTLMNA | |
| SCHEMBL12415880 | 0.84 | MAPT (0.54) | RXFP1THRBMAPTGRM5LMNA | |
| SCHEMBL12415900 | 0.81 | MAPT (0.48) | RXFP1THRBMAPTLMNAPOLB | |
| SCHEMBL12415875 | 0.79 | MAPT (0.54) | RXFP1MAPTLMNA | |
| SCHEMBL12415901 | 0.78 | SHMT2 (0.45) | RXFP1MAPTLMNAFAAH | |
| SCHEMBL12415864 | 0.78 | MAPT (0.53) | RXFP1MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172217-A1 | RING-FUSED MORPHOLINE DERIVATIVE HAVING PI3K-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2011-07-14 | — | — | US | disclosed |
| US-20110172217-A1 | RING-FUSED MORPHOLINE DERIVATIVE HAVING PI3K-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172217-A1 | RING-FUSED MORPHOLINE DERIVATIVE HAVING PI3K-INHIBITING ACTIVITY | PIK3R3, AKT3, AKT2 | HCAR2 2806/4885RXFP1 3699/4885THRB 2639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.